T. H. Johnston

发表

Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism

J. Brotchie, C. S. Khademullah, R. Warre, 2011, Neurobiology of Disease.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

Alix M B Lacoste, A. Lang, J. Brotchie, 2019, Neuropharmacology.

Reproducibility of a Parkinsonism‐related metabolic brain network in non‐human primates: A descriptive pilot study with FDG PET

D. Eidelberg, Y. Guan, J. Brotchie, 2015, Movement disorders : official journal of the Movement Disorder Society.

Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

J. Brotchie, D. Salomonczyk, N. Barnes, 2010 .

The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

J. Brotchie, S. Fox, T. H. Johnston, 2013, Pharmacological Reviews.

Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease

J. Brotchie, Joohyung Lee, T. H. Johnston, 2008, Synapse.

Pridopidine, a clinic‐ready compound, reduces 3,4‐dihydroxyphenylalanine‐induced dyskinesia in Parkinsonian macaques

J. Brotchie, P. Ravenscroft, S. Fox, 2019, Movement disorders : official journal of the Movement Disorder Society.

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein

J. Brotchie, T. Dawson, T. H. Johnston, 2011, PloS one.

A critique of available scales and presentation of the non‐human primate dyskinesia rating scale

Qin Li, E. Bézard, J. Brotchie, 2012, Movement disorders : official journal of the Movement Disorder Society.

The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease

J. Brotchie, S. Fox, T. H. Johnston, 2011, Movement disorders : official journal of the Movement Disorder Society.

The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset

J. Brotchie, S. Fox, T. H. Johnston, 2012, PloS one.

Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases

M. Wuest, J. Brotchie, Jennifer Dufour, 2022, EJNMMI Research.

Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time

J. Brotchie, S. Fox, T. H. Johnston, 2011, The Journal of Neuroscience.

Fatty acid amide hydrolase (FAAH) inhibition reduces L-DOPA-induced hyperactivity in the MPTP-lesioned non-human primate model of Parkinson’s disease

S. Fox, T. H. Johnston, P. Huot, 2010 .

The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

J. Brotchie, S. Fox, R. D. de Bie, 2008, Movement disorders : official journal of the Movement Disorder Society.

Drugs in development for Parkinson's disease.

J. Brotchie, T. H. Johnston, 2004, Current opinion in investigational drugs.

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA

J. Brotchie, S. Fox, T. H. Johnston, 2012, Neurobiology of Aging.

Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

L. Hazrati, J. Brotchie, S. Fox, 2010, Movement disorders : official journal of the Movement Disorder Society.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia

J. Brotchie, S. Fox, T. H. Johnston, 2018, The Journal of Pharmacology and Experimental Therapeutics.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

J. Brotchie, P. Ravenscroft, S. Fox, 2018, Neuropharmacology.

The Opioid System in Levodopa-Induced Dyskinesia

P. Ravenscroft, T. H. Johnston, M. Hill, 2014 .

Advances in the delivery of treatments for Parkinson’s disease

J. Brotchie, S. Fox, T. H. Johnston, 2005, Expert opinion on drug delivery.

Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit

J. Brotchie, P. Ravenscroft, M. Bentley, 2013, Movement disorders : official journal of the Movement Disorder Society.

Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease

J. Brotchie, S. Fox, T. H. Johnston, 2010, Movement disorders : official journal of the Movement Disorder Society.

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson’s Disease

J. Brotchie, P. Ravenscroft, T. H. Johnston, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na+,K+-ATPase α3 Missense Mutant Mice

J. Pratt, J. Roder, J. Brotchie, 2013, PloS one.

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

J. Brotchie, T. H. Johnston, Gabriela Reyes, 2010, Molecular Neurodegeneration.

The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.

R. Depoortère, J. Brotchie, A. Newman-Tancredi, 2020, Parkinsonism & related disorders.

Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

J. Brotchie, S. Fox, T. H. Johnston, 2010, Journal of Pharmacology and Experimental Therapeutics.

A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease

J. Schneider, B. Waterhouse, J. Brotchie, 2020, Experimental Neurology.

Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease

J. Brotchie, S. Fox, Chengwen Sun, 2011, Journal of Pharmacology and Experimental Therapeutics.

The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

J. Brotchie, S. Fox, T. H. Johnston, 2010, Movement disorders : official journal of the Movement Disorder Society.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

J. Brotchie, S. Fox, T. H. Johnston, 2013, Parkinsonism & related disorders.

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque

J. Brotchie, S. Fox, T. H. Johnston, 2012, Neurobiology of Aging.

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease

J. Brotchie, T. H. Johnston, N. Callizot, 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

J. Brotchie, T. H. Johnston, Gabriela Reyes, 2016, PloS one.

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats

M. Amalric, J. Brotchie, T. H. Johnston, 2008, Neuropharmacology.

Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

V. Voon, J. Brotchie, S. Fox, 2006, Movement disorders : official journal of the Movement Disorder Society.

Subcellular redistribution of the synapse‐associated proteins PSD‐95 and SAP97 in animal models of Parkinson&s disease and L‐DOPA‐induced dyskinesia

G. Collingridge, C. Garner, J. Brotchie, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

Susan H. Fox, J. Brotchie, S. Fox, 2012, Neuropharmacology.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

J. Brotchie, S. Fox, T. H. Johnston, 2015, Behavioural pharmacology.

Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains

J. Brotchie, C. S. Khademullah, R. Warre, 2011, Journal of Neuroscience Methods.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset

J. Brotchie, S. Fox, T. H. Johnston, 2014, Neuropharmacology.

The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque

J. Brotchie, A. Newman-Tancredi, S. Fox, 2015, Neuropharmacology.

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

V. Voon, J. Brotchie, S. Fox, 2006, Archives of neurology.

Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease

L. Hazrati, J. Brotchie, S. Fox, 2012, Movement disorders : official journal of the Movement Disorder Society.

Drugs in development for Parkinson's disease: an update.

J. Brotchie, T. H. Johnston, 2006, Current opinion in investigational drugs.

New insights into the organization of the basal ganglia

J. Brotchie, S. Fox, T. H. Johnston, 2009, Current neurology and neuroscience reports.

A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances l‐DOPA benefit in parkinsonian primates

J. Brotchie, S. Fox, Joohyung Lee, 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Experimental Models of l-DOPA-Induced Dyskinesia.

T. H. Johnston, E. Lane, 2011, International review of neurobiology.

Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

J. Brotchie, S. Fox, T. H. Johnston, 2006, Movement disorders : official journal of the Movement Disorder Society.

Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque

J. Brotchie, S. Fox, T. H. Johnston, 2013, The European journal of neuroscience.

Effects of Opioid Antagonists on l-DOPA-Induced Dyskinesia in Parkinson's Disease

J. Brotchie, S. Fox, T. H. Johnston, 2009 .

L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

J. Brotchie, S. Fox, T. H. Johnston, 2012, Journal of Pharmacology and Experimental Therapeutics.

NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model

J. Schneider, J. Brotchie, T. H. Johnston, 2020, Movement disorders : official journal of the Movement Disorder Society.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque

J. Brotchie, S. Fox, K. Szeliga, 2013, Neuropharmacology.

Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na+,K+-ATPase α3 Missense Mutant Mice

J. Pratt, J. Roder, J. Brotchie, 2013, PLoS ONE.

The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

J. Brotchie, S. Fox, T. H. Johnston, 2013, Pharmacological Reviews.

Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia

J. Brotchie, T. H. Johnston, N. Visanji, 2024, Neuropharmacology.

J. Brotchie, S. Fox, T. H. Johnston, 2011, Journal of Pharmacology and Experimental Therapeutics.

α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques

J. Brotchie, T. H. Johnston, N. Visanji, 2009, Journal of Pharmacology and Experimental Therapeutics.